There are a number of clinical trials that have helped shaped the current practice guidelines in the practice of neuro-ophthalmology. The key neuro-ophthalmology trials are the Optic Neuritis Treatment Trial (ONTT), the Ischemic Optic Neuropathy Decompression Trial (IONDT), and the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Other studies summarized include the use of Intravenous Immunoglobulin in inflammatory demyelinating optic neuritis, and the use of idebenone in Leber Hereditary Optic Neuropathy. Surgical trials have also had a high impact on neuroophthalmology practice, such as the International Subarachnoid Aneurysm Trial (ISAT), Corticosteroid Randomization after Significant Head Injury (CRASH), Sub-Group Analysis on transient monocular blindness in the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Assessment Group for Lysis in the Eye (EAGLE) Study. Major multiple sclerosis trials include, Controlled High Risk Avonex Multiple Sclerosis Trial (CHAMPS), Early Treatment of Multiple Sclerosis (ETOMS), Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT), and the Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis in Subjects Presenting with a Clinically Isolated Syndrome (PreCISe).
- The Ophthalmology Clinical Trials Handbook
Start / End Page
International Standard Book Number 13 (ISBN-13)